Brian D. Weiss, MD
Pediatric Hematology - Oncology
Employed Provider
Accepting New Patients
On This Page
About Me
Dr. Brian Weiss is the pediatric division chief of hematology/oncology/stem cell transplant at Riley Children's Health. He comes to Riley Children's after his tenure at Cincinnati Children's Hospital Medical Center, where he previously served as professor of clinical pediatrics in the division of oncology, medical director of solid tumors, associate inpatient director, associate director of safety and compliance of the cancer and blood diseases institute. Prior to his time there, he completed residency and a fellowship at the University of California at San Francisco.
With his clinical expertise, he has stewarded multiple national clinical trials, particularly focusing on novel therapies for neuroblastoma and Neurofibromatosis Type 1 associated plexiform neurofibromas.
Dr. Weiss is excited to lead the dynamic group at Riley Children's and spearhead novel therapies for children with cancer and blood diseases.
Locations
Riley Pediatric Cancer & Blood Disorders
575 Riley Hospital Dr
Hematology/Oncology MSA
Indianapolis, IN, 46202
Get Directions 317.944.2143Specialties & Details
- Pediatric Hematology - Oncology
- School of Medicine: Northwestern University Feinberg School of Medicine, Chicago, IL
- Residency: University of California School of Medicine, San Francisco, CA
- Fellowship: University of California School of Medicine, San Francisco, CA
- Riley Physicians
- IU Health Medical Group
Clinical Trials
Explore the ongoing clinical trials this provider is involved in and learn about the eligibility requirements for each one. Search the clinical trial directory to find additional clinical trials.
A Phase 1 study of GRN163L (Imetelstat, IND# 170891, NSC# 754228) in combination with fludarabine and cytarabine for patients with acute myeloid leukemia that is in second or greater relapse or that is refractory to relapse therapy; myelodysplastic syndrome or juvenile myelomonocytic leukemia in first or greater relapse or is refractory to relapse therapy
View DetailsPhase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Azd1390 (Nsc#852149, Ind# 172675) when Combined with Focal Radiation in Pediatric Patients with High Grade Glioma
View DetailsDt2216 (Nsc#850950, Ind# 170973) in Combination with Irinotecan for Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors: A Phase 1 Study with Phase 2 Feasibility Cohort for Fibrolamellar Carcinoma
View Details